← Eichor
Condition: Gastroenteropancreatic Neuroendocrine Tumor Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Gastroenteropancreatic Neuroendocrine Tumor

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phase 1/Phase 2 · 15 location(s) · Phanes Therapeutics · NCT05652686An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancr
Phase 3 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT05884255Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown
Phase 2 · 6 location(s) · Centre Hospitalier Universitaire Dijon · NCT04325425Spanish Series of Patients Treated With the Radionuclide Lutetium177
Phase N/A · 20 location(s) · Sociedad Española de Medicina Nuclear e Imagen Molecular · NCT04949282Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
Phase 1 · 2 location(s) · Emory University · NCT07150546Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
Phase 1 · 9 location(s) · RayzeBio, Inc. · NCT07165132Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Phase 1/Phase 2 · 19 location(s) · Perspective Therapeutics · NCT05636618Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Phase 1 · 6 location(s) · Novartis Pharmaceuticals · NCT07006727Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 17
Phase 3 · 54 location(s) · RayzeBio, Inc. · NCT05477576Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract,
Phase 2 · 4 location(s) · Aadi Bioscience, Inc. · NCT05997056Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendoc
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06427798Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionucl
NA · 5 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06256705A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
Phase N/A · 1 location(s) · Novartis Pharmaceuticals · NCT07635316PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)
Phase 3 · 2 location(s) · Tata Memorial Hospital · NCT07185672Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Meta
Phase 2 · 4 location(s) · University Hospital, Bordeaux · NCT04837885Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENs
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT06356467Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroend
Phase 4 · 1 location(s) · Vanderbilt-Ingram Cancer Center · NCT06016855Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT05196087Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Phase 3 · 65 location(s) · Novartis Pharmaceuticals · NCT06784752A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Pro
Phase 2 · 1 location(s) · National Cancer Institute, Naples · NCT04893785Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Sol
Phase 1/Phase 2 · 5 location(s) · Molecular Partners AG · NCT07278479A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-
Phase 2 · 1 location(s) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · NCT06505395DCEUS to Assess Treatment Response to PRRT in GEP-NET
NA · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT07319416Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric P
Phase 1 · 5 location(s) · ITM Solucin GmbH · NCT06441331Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid
Phase 1/Phase 2 · 1 location(s) · Mainline Biosciences (Shanghai) Co., Ltd · NCT06840821Observational Study on GEP-and Pulm-NET Treated at FPG
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06402695Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Phase 1 · 20 location(s) · SystImmune Inc. · NCT07080242Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg
Phase N/A · 1 location(s) · University Hospital, Strasbourg, France · NCT07302100Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
Phase N/A · 2 location(s) · Methodist Health System · NCT04090034Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastr
Phase 2/Phase 3 · 1 location(s) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · NCT07165886
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.